Drug shortages in tertiary care hospitals always limit the health system's ability to provide quality care to the patients. Immediately following the existing shortage of 5 different oncology drugs in Pakistan, numerous patients are finding themselves in a desperate state of no cure for their illness. Cardinal factors responsible for this unfortunate situation include interruption in vendor supplies and regulatory authorities' issues related to approval and pricing. Effective review of policies by regulatory authorities for availability of drugs will certainly avoid this miserable condition in the future and ensure continuation of high-quality care to patients by health care systems.
Standard cancer chemotherapy has been used for years as a primary treatment in pediatric and adult populations. Occasionally practitioners have to face shortage of these cytotoxic agents, which means either an inappropriate treatment or a delay in therapeutic management.
1,2 For a country like Pakistan, shortage of cytotoxic drugs has always been a worry, 3 but the recent shortage in the first half of 2018 is actually a complication, affecting more than one population with cancer. Shortage of these conventional agents has created remarkable challenges for both patients and health care providers. Safety, quality of treatment, risk from clinical failure, and cost are becoming the major concerns of scarcity of anticancer drugs.
Oncology Drugs on the Top of Shortage List
The prominent agents that are in shortage from early 2018 are vinblastine, daunorubicin, dacarbazine, and dactinomycin, whereas MESNA (sodium 2-mercaptoethane sulfonate) is short from the middle of 2018. With MESNA not available, use of ifosfamide and cyclophosphamide is questionable and virtually impossible especially at high doses. Thus, for any patient needing high-dose cyclophosphamide or ifosfamide, continuing with these agents without MESNA can lead to fatal hemorrhagic cystitis. 4 MESNA acts as a protecting agent against this toxicity and is the major part of the European EE99 5 and American COG0031 Ewing sarcoma protocols. 6 The remaining agent for Ewing's treatment, dactinomycin, 7 has already run short in supply.
Vinblastine and dacarbazine are vital drugs for Hodgkin's lymphoma ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) chemotherapy. 8 Daunorubicin, an anthracycline-based product, is the major part of induction chemotherapy recommended for the treatment of precursor B-cell acute lymphoblastic leukemia. 
Oncology Drug Shortages and the Situation of the Patients
For the 207.7 million population of Pakistan, the number of newly diagnosed cases of cancer from the data of GLOBOCAN 2018 by the International Agency for Research on Cancer is about 0.174 million for both sexes and all ages. 10 The treatment of almost all types of cancers composes combinations of different medications, which control or prevent the disease process in a collaborative way. The absence of even a single agent will affect the survival of the patient. Therefore, for the patients undergoing active treatment for Hodgkin's lymphoma, precursor B-cell acute lymphoblastic leukemia, and Ewing sarcoma during this period of shortage, the paucity of these highlighted agents is clearly indicating the risk and impact on treatment uncertainty; and if these agents are not managed on an urgent basis, then the chances of putting treatment on hold leading to poor outcomes will be obvious. On the other side of the coin, there is another group of patients who are newly diagnosed. These patients may have to consider treatment from other centers with sufficient supplies of the drugs, which in case of our country is very difficult, since the shortages usually happen across the national due to impeding supply process via a single distributer and the lack of primary manufacturing units of cytotoxic drugs. The other limited ways left for this population include either consideration of substitution of the scant agents with other suitable ones or the switching to an alternative chemotherapy regimen at the same center. However, in the latter cases, the guarantee of excellent treatment response with no added risk of adverse events may be compromised as compared with the default treatment plan.
Root Cause of Oncology Drug Shortages and Management Options
Drug shortages are multifactorial, involving issues related to raw and bulk material, demand/supply, production/manufacturing, distribution, and regulatory authorities. 11 The main reason for these current drug shortages as per the distributer is the unavailability of quality active pharmaceutical ingredients at the manufacturers' end. This unavailability has affected us to this extent. Why? The answer lies in the fact that we are managing all these agents from only a single source approved by the Drug Regulatory Authority of Pakistan (DRAP). Thus, it is time for oncologists, patients, and other health communities to raise their voice for the only prompt solution of this alarming situation, which is to advocate for the need for import of alternative brands at the DRAP level. Availability of these and other cytotoxic agents from other multiple sources is inevitable, so we should have urgent approval of different sources by DRAP for direct import. At the legislative level, there must be a provision in law for direct and timely import of these life-extending and lifesaving drugs from approved alternate sources.
On the other hand, since there is no manufacturing location in Pakistan currently involved in the production of these agents, the involvement of the national locations of the international manufacturers in Pakistan by DRAP for manufacturing purpose can be another way to cope with this situation. Keeping in view the demand, engaging a few manufacturers will allow them to participate more effectively since it will make them look for more revenue that has always been a major concern. Although it is a timetaking process, but it will also definitely help in managing future drug shortages.
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